This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Basic classification information | |
|---|---|
| ICD-10 | E76.2 |
| Special Copayment Reduction code | V117 |
| Main Korean name | Beta-glucuronidase deficiency (Sly syndrome, MPS VII) |
| Synonyms | Sly syndrome, MPS VII, Mucopolysaccharidosis type VII |
| 1. History | 2. Causes |
| 3. Genetics | 4. General epidemiology |
| 5. Pathophysiology | 6. Symptoms |
| 7. Signs | 8. Screening |
| 9. Diagnosis | 10. Treatment |
| 11. Prognosis | 12. Prevention |
| 13. References | |
Mucopolysaccharidosis type VII (MPS VII), also known as Sly syndrome, was first described in 1973 by the American pediatrician William S. Sly. Sly and colleagues identified increased urinary excretion of glucuronic acid-containing glycosaminoglycans (GAG) in pediatric patients with dysostosis multiplex, hepatosplenomegaly, distinctive facies, and intellectual disability, and showed markedly decreased beta-glucuronidase (GUSB) activity in leukocytes and fibroblasts. This report established a new type of mucopolysaccharidosis in which lysosomal enzyme deficiency causes GAG accumulation, and became the foundation for subsequent enzyme diagnosis and molecular genetic research.
In 1984, cDNA cloning of the GUSB enzyme was achieved, and in 1988 the gene was shown to be located on chromosome 7q11.21-q11.22. In the 1990s, various GUSB gene mutations were identified, and studies to elucidate the genotype–phenotype correlation were actively carried out. With the identification of a very broad clinical spectrum, from the extremely severe prenatal form presenting as hydrops fetalis to mild forms surviving into adulthood, MPS VII became established as one of the MPS with the greatest phenotypic heterogeneity.
An important turning point in treatment history was the accelerated approval by the US FDA in 2017 of vestronidase alfa (vestronidase alfa-vjbk, brand name Mepsevii), which became the first approved enzyme replacement therapy (ERT) for MPS VII. Approval followed in Europe in 2018, expanding global access to treatment. In Korea, this disease is included in the rare and severe intractable disease Special Copayment Reduction (V117), making patients eligible for medical expense support.
MPS VII is caused by genetic deficiency of the lysosomal hydrolase beta-glucuronidase (beta-D-glucuronidase, EC 3.2.1.31). This enzyme is responsible for cleaving the non-reducing terminal glucuronic acid residues in the degradation of GAGs such as heparan sulfate, dermatan sulfate, and chondroitin sulfate. When enzyme activity is deficient, these GAGs accumulate progressively within the lysosome, cell function is impaired, and progressive lesions appear across various organs.
The causative gene is GUSB, located on chromosome 7q11.21 and composed of 12 exons. More than 100 pathogenic variants have been reported so far, with missense mutations being the most common. p.L176F, p.R382C, p.R382H, and p.W528C are known as representative variants. Some mutations cause severe loss of enzyme activity (null mutations) and are associated with the severe phenotype, while variants retaining some residual enzyme activity tend to be associated with the mild phenotype.
MPS VII is inherited in an autosomal recessive manner, so disease develops only when one pathogenic variant allele is inherited from each carrier parent. Carriers have no clinical symptoms, and enzyme activity is maintained at about 50% of normal.
The GUSB gene is located on chromosome 7q11.21 and contains 12 exons spanning about 20 kb of genomic DNA. The mature protein consists of 651 amino acids and functions as a homotetramer within the lysosome. More than 100 pathogenic variants are currently listed in the HGMD (Human Gene Mutation Database).
In the phenotype–genotype correlation, the p.L176F variant shows a strong association with the severe hydrops fetalis phenotype, while the p.R382C variant is associated with a relatively mild clinical course. Compound heterozygous forms are more common than homozygous ones, and the severity of the clinical phenotype is determined by the degree of residual enzyme activity of each variant. In some patients enzyme activity falls below 1% of normal, whereas in mild patients residual activity of 5–10% may be maintained.
Prenatal diagnosis is possible by measuring enzyme activity in fetal cells obtained through chorionic villus sampling (CVS) or amniocentesis, or by molecular genetic analysis when a familial mutation has already been identified. Preimplantation genetic testing (PGT-M) is also theoretically applicable. In genetic counseling, the sibling recurrence risk of 25% should be explained and the importance of carrier testing emphasized.
MPS VII is among the rarest types of MPS, with fewer than 400 cases reported in the literature worldwide to date. The incidence is estimated at about 1 in 300,000–1,000,000 births, but it is difficult to calculate an exact figure owing to the small number of cases. Specific regional clustering is not as prominent as in other types of MPS, but relatively many patients have been reported in cohorts from the Iberian Peninsula (Spain, Portugal).
There is no difference in incidence by sex, and it occurs in equal proportions in men and women. Age at diagnosis varies greatly according to clinical phenotype. The hydrops fetalis form is detected by prenatal ultrasound or stillbirth, the moderate to severe form shows symptoms within 1–3 years after birth, and the mild form may be diagnosed after school age or in adulthood.
Diagnostic delay is common, and the disease is often mistaken for other diseases because of nonspecific symptoms (recurrent respiratory infections, skeletal abnormalities, etc.). Expansion of newborn or infant screening programs remains an important task for early diagnosis. In Korea, the number of patients registered for Special Copayment Reduction is extremely small, so domestic prevalence data are not yet sufficient.
Beta-glucuronidase contributes to GAG degradation by sequentially cleaving terminal non-reducing glucuronic acid residues of heparan sulfate, dermatan sulfate, chondroitin 4-sulfate, chondroitin 6-sulfate, and others within the lysosome. In the absence of enzyme activity, undegraded GAG fragments accumulate progressively within the lysosome, causing lysosomal swelling and cellular dysfunction.
GAG accumulation occurs in tissues throughout the body, and is particularly prominent in the liver, spleen, bone marrow, connective tissue, brain, heart valves, cornea, and bone. Lysosomal dysfunction secondarily causes complex cellular pathology such as impaired autophagy pathways, mitochondrial dysfunction, increased generation of reactive oxygen species (ROS), and increased secretion of inflammatory cytokines. In the nervous system, lysosomal accumulation in neurons promotes apoptosis, leading to cognitive decline and neurodegeneration.
In the skeletal system, GAG accumulation in cartilage and bone matrix causes growth plate dysfunction and ossification defects, producing dysostosis multiplex. In the heart, GAG deposition in valvular interstitial cells causes valve thickening and dysfunction. GAG accumulation in the upper airway causes airway narrowing and obstructive sleep apnea and raises the risk of recurrent respiratory infections. Thus the pathology of MPS VII is understood as a complex mechanism that goes beyond simple substrate accumulation and involves cascading damage to multiple cell signaling pathways.
The clinical picture of MPS VII has a very broad phenotypic spectrum, ranging from the extremely severe neonatal/fetal form to the mild adult (attenuated) form.
In severe forms, developmental delay, intellectual disability (mild to severe), and delayed language development are prominent. In some cases development appears normal at first, with regression appearing after 2–4 years of age. Behavioral problems (hyperactivity, aggression) and sleep disturbances are also common. In mild forms, cognitive function is relatively preserved, and some complete the regular education curriculum.
Recurrent upper and lower respiratory tract infections, chronic cough, and otitis media are common. Obstructive sleep apnea occurs due to upper airway narrowing and tracheomalacia, and in severe cases continuous positive airway pressure ventilation (CPAP) or tracheostomy is needed. Restrictive lung disease due to lung parenchymal involvement has also been reported.
Dysostosis multiplex—macrocephaly, rib thickening, incomplete wedging of the vertebrae, acetabular dysplasia, and long bone deformity—occurs. Joint stiffness and limited range of motion, hand and foot deformities, scoliosis, and thoracolumbar kyphosis progress. Final height is small owing to growth delay.
Hepatosplenomegaly is observed in nearly all patients, and umbilical and inguinal hernias are common. Gastrointestinal symptoms such as dyspepsia and diarrhea may also occur.
Characteristic findings appear in combination on physical examination.
Coarse facies: a large head (macrocephaly), flat nose, thick lips, protruding mandible, and thick tongue (macroglossia) are typical. Orbital hypertelorism and a thick scalp are also observed. The degree of facial features varies greatly with the severity of the phenotype, and in mild forms facial features are almost absent or very mild.
Corneal clouding occurs in most severe patients, and retinal degeneration, optic atrophy, reduced vision, and increased intraocular pressure (glaucoma) may accompany. Regular ophthalmologic follow-up is needed.
Cardiac valve disease (mitral regurgitation, aortic valve insufficiency) is a major cause of morbidity. Cardiomyopathy and heart failure are also reported in severe cases. Regular echocardiography is essential.
Extensive skin pigmentation resembling Mongolian spots may occur. Thick skin and hypertrichosis are also observed. When neurological findings due to spinal cord compression (conus symptoms) occur, neurosurgical intervention is needed.
The most severe phenotype, in which ascites, placental edema, and subcutaneous edema are found on prenatal ultrasound. Most result in stillbirth or neonatal death, and MPS VII must be considered in the differential diagnosis of non-immune hydrops fetalis.
A systematic newborn screening (NBS) program for MPS VII has not yet been standardized in Korea or abroad, but enzyme activity measurement methods based on dried blood spots (DBS) have been developed at the research level. A method that uses a fluorogenic substrate or tandem mass spectrometry (MS/MS) to measure beta-glucuronidase activity in DBS is evaluated as a promising screening tool.
Quantitative analysis of urinary GAG is a relatively simple first-line screening method, confirming increased excretion of dermatan sulfate, heparan sulfate, and chondroitin sulfate. The simple urinary GAG colorimetric method (toluidine blue spot test, Berry test) and quantitative electrophoresis (GAG electrophoresis) are used in clinical practice. However, this method can give false negatives, so confirmatory testing must be performed together.
In clinically suspicious situations, lysosomal enzyme activity testing should be performed immediately. Clinically suspicious situations include non-immune hydrops fetalis, infants with hepatosplenomegaly of unknown cause, and a combination of recurrent respiratory infections, coarse facies, and skeletal abnormalities. Early diagnosis is the key to maximizing treatment effect.
Definitive diagnosis is made by demonstrating markedly decreased beta-glucuronidase activity, at 1–10% or less of normal controls, in leukocytes (lymphocytes, granulocytes) or skin fibroblasts. A fluorometric assay using a fluorogenic substrate (4-methylumbelliferyl-beta-D-glucuronide) is used as the standard.
Pathogenic variants are confirmed by GUSB gene sequencing (Sanger sequencing or next-generation sequencing, NGS). The diagnosis is confirmed when pathogenic variants are identified in both alleles, and this helps in predicting prognosis. Molecular analysis is particularly important when the enzyme activity result is borderline.
Vestronidase alfa (vestronidase alfa-vjbk, brand name Mepsevii) is the first and only ERT approved for the treatment of MPS VII, by the FDA in 2017 and the EMA in 2018. As recombinant human beta-glucuronidase, it is given at 4 mg/kg as a 4-hour intravenous infusion once every 2 weeks. Clinical trials demonstrated significant effects on walking function, pulmonary function, physical growth, and reduction of GAG biomarkers. Limited passage across the blood–brain barrier means the effect on central nervous system lesions is inadequate.
It has been performed at some centers in cases with severe neurological involvement, but the evidence in MPS VII is not as strong as in other MPS. The neurological functional status before transplantation has an important influence on the effect of transplantation, so careful patient selection after early diagnosis is needed.
Adeno-associated virus (AAV)-based gene therapy has shown promising results in animal models, and clinical trials are ongoing. Systemic therapy using liver-directed AAV vectors and central nervous system-targeted therapy through direct cerebrospinal fluid injection are being studied.
The prognosis of MPS VII differs starkly according to clinical phenotype. The hydrops fetalis form mostly leads to stillbirth or neonatal death, with extremely low survival. In the typical severe form, death often occurs in the teens to twenties due to progressive neurological regression, recurrent respiratory infections, and cardiac complications. Upper airway obstruction and cardiac valve disease are the main causes of death.
In the mild form (attenuated form), cognitive function is partly preserved, and cases surviving to the 40s–50s have been reported. Since the introduction of ERT, reduced body GAG burden and improved non-neurological function have been seen in some patients, but follow-up data on whether long-term survival improves are still limited. Prompt initiation of ERT after early diagnosis is known to be the most effective for suppressing progression of non-neurological symptoms.
Neurological decline is not adequately suppressed by current ERT alone, and future development of central nervous system-targeted therapies (intraventricular ERT, gene therapy) is expected to be the key to improving prognosis. Accumulation of natural history data through multicenter registries is important for treatment evaluation and prognostic counseling.
Because MPS VII is an autosomal recessive genetic disease, the core of primary prevention is genetic counseling and prenatal diagnosis. Siblings of the patient have a 25% recurrence risk, and identifying and counseling carrier parents is important. If one parent is a patient with MPS VII and the spouse is a carrier, 50% of the children may be affected, so intensive genetic counseling is required.
Carrier testing can be performed accurately by molecular genetic methods once the pathogenic variant in the family has been identified. Enzyme activity measurement alone may be uncertain in distinguishing carriers from normal individuals, so molecular testing is used as a complement.
Whether the fetus is affected can be determined through prenatal diagnosis (CVS, amniocentesis), and avoiding implantation of affected embryos through preimplantation genetic diagnosis (PGT-M) is also an option. When early diagnosis is made, a secondary prevention strategy of starting ERT from the neonatal period to minimize irreversible organ damage should be pursued in parallel. The introduction of newborn screening (DBS-based enzyme assay) is expected to greatly expand future opportunities for early treatment.